Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Hui-Chun Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University…. Hauptthemen laut MEDLINE: Hypertension, Kidney, Sympathectomy, Catheter Ablation. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Radiofrequency renal denervation (RF RDN) is recognized as an adjunct therapy for hypertension. This study evaluated the cost‐effectiveness of RF RDN for the Taiwanese healthcare system using results from the SPYRAL HTN‐ON MED randomized, sham‐controlled trial. A decision‐analytic Markov model projected clinical events, costs, and quality‐adjusted life‐years (QALYs) for RF RDN versus standard‐of‐care (SoC) in an Asian population context. Clinical event risk reductions from treatment effects on office‐based systolic blood pressure (oSBP) were derived from a meta‐regression study of 47 hypertension trials. SPYRAL HTN‐ON MED demographics and results (oSBP reduction of 4.9 mmHg against sham) were used in the base case analysis. The incremental cost‐effectiveness ratio (ICER) was assessed against a willingness‐to‐pay (WTP) threshold of three million Taiwan dollars (TWD) per QALY gained. Compared to SoC, RF RDN was projected to reduce clinical events, with relative risks of 0.80, 0.88, and 0.74 for stroke, myocardial infarction (MI), and heart failure (HF), respectively. The incremental costs and QALYs were 216 381 TWD and 0.25, respectively, resulting in an ICER of 850 932 TWD per QALY gained. The ICER was cost‐effective across a broad range of uncertainty analyses. Model‐based projections adjusted for East Asian event rates suggest RF RDN may significantly reduce events, making it a cost‐effective intervention in the Taiwanese healthcare system for treating uncontrolled hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
- Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan.
- Wing Tech Inc., Menlo Park, California, USA.
- Medtronic Taiwan Ltd., Taipei City, Taiwan.
ORCID-Profile: Tzung-Dau Wang
Zitieren
APA
Huang, H. C., Cao, K. N., Ryschon, A. M., Phay, K. W., Wang, T. D., & Pietzsch, J. B. (2025). Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70090
Vancouver
Huang HC, Cao KN, Ryschon AM, Phay KW, Wang TD, Pietzsch JB. Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70090
BibTeX
@article{Huang2025,
author = {Huang, Hui-Chun and Cao, Khoa N and Ryschon, Anne M and Phay, Kee-Wong and Wang, Tzung-Dau and Pietzsch, Jan B},
title = {Cost‐Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70090}
}
EUVIMED